CG Oncology jumps after Phase 3 bladder cancer trial succeeds
The pick
CG Oncology (CGON) had the biggest jump in trading volume compared with its usual level on November 16, 2026. Volume was 9.0x its 30-day average, and the stock rose 13.95%.
What happened
On November 16, 2026, CG Oncology announced positive topline results from PIVOT-006, a Phase 3 registrational trial. The trial tested cretostimogene grenadenorepvec in patients with intermediate-risk and high-grade Ta non-muscle invasive bladder cancer after complete tumor resection. The company said the trial met its primary endpoint.
Cretostimogene reduced the risk of recurrence by 68% compared with the control arm. The hazard ratio was 0.32 (95% CI: 0.23, 0.45; p<0.0001). Median follow-up was 17 months as of October 26, 2026. The company said there were no Grade 3 or greater treatment-related adverse events and no treatment-related discontinuations.
The trial enrolled 367 patients across about 90 sites in the United States and Canada. It compared cretostimogene with surveillance. The company said there are currently no U.S. FDA approved adjuvant treatment options for this group of about 50,000 patients.
The company also said that, based on FDA feedback, its first BLA submission in BCG-unresponsive bladder cancer will be broadened to include high-grade papillary-only disease. It now expects to complete that submission before the end of March 2027. The company cautioned that topline data come from a preliminary analysis and may change after a fuller review.
Sources: [company announcement, SEC filing] [press release]
What news reports said
Yahoo Finance reported that options traders were targeting SMMT and CGON after their respective news. [Yahoo Finance]
The numbers
Previous close: $74.40
Close: $84.78
Change: +13.95%
Volume: 9,852,507
30-day average volume: 1,099,238
Volume multiple: 9.0x
Behind the move: a company press release
CGON's most unusual trading day in 2 years
Its sector (Health Care, XLV) moved -0.51% that day
What to watch
December 2, 2026: PIVOT-006 topline results are scheduled for a late-breaking podium presentation at the Society of Urologic Oncology Annual Meeting.
March 2027: The company anticipates completing its initial BLA submission in BCG-unresponsive bladder cancer.
Q2 2027: The company anticipates a second BLA submission in intermediate-risk and high-grade Ta bladder cancer, supported by PIVOT-006 data.
Source: [SEC filing]
Pro: CGON has had 6 earlier days at 5x+ normal volume since 2024. Pro members see what it did over the next 5 and 20 trading days after each one. See Pro
Curious what usually happens after a stock trades 9x its normal volume? Pro members can ask questions like that in plain English and get results across every U.S. stock since 2016. See what Pro includes
More coverage
Pro: 9 more stocks made Monday's unusual-volume top 10, the next one at 7.2x its normal level. Pro members can also test any setup in plain English on every U.S. stock since 2016 ("what happened after stocks traded 9x their normal volume?"), and get the full top 10 every morning plus intraday alerts on big moves. 25 of 25 founding spots left: $9/month, locked in for as long as you stay ($14 after Dec 31 or when the spots are gone). Claim a founding spot